[{"id":"ad1d963e-b163-427e-be70-2d37437a6605","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471841","created_at":"2026-03-28T01:44:38.203Z","updated_at":"2026-03-28T01:44:38.203Z","phase":"Phase 2","brief_title":"Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax","source_id_and_acronym":"NCT07471841","lead_sponsor":"Timothy Pardee","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Rezlidhia (olutasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/01/2026","start_date":" 05/01/2026","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2026-03-13"},{"id":"ef9e7260-d9e3-483f-aa0a-3b74c6c79ebc","acronym":"VANGUARD","url":"https://clinicaltrials.gov/study/NCT07469735","created_at":"2026-03-28T01:44:12.900Z","updated_at":"2026-03-28T01:44:12.900Z","phase":"","brief_title":"Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma","source_id_and_acronym":"NCT07469735 - VANGUARD","lead_sponsor":"Huashan Hospital","biomarkers":" IDH1 • IDH2","pipe":"","alterations":" ","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-13"},{"id":"8ecfd71e-09dc-439f-af05-bbb7a6382e68","acronym":"","url":"https://clinicaltrials.gov/study/NCT07130695","created_at":"2025-08-23T13:32:09.751Z","updated_at":"2025-08-23T13:32:09.751Z","phase":"Phase 1","brief_title":"Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation","source_id_and_acronym":"NCT07130695","lead_sponsor":"Virginia Commonwealth University","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rezlidhia (olutasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/31/2025","start_date":" 10/31/2025","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2029","study_completion_date":" 10/31/2029","last_update_posted":"2025-08-19"},{"id":"17c029cc-5449-4ba9-99f6-13ebaefd3227","acronym":"EVOLVE 1","url":"https://clinicaltrials.gov/study/NCT07075016","created_at":"2025-07-26T13:34:40.222Z","updated_at":"2025-07-26T13:34:40.222Z","phase":"Phase 3","brief_title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","source_id_and_acronym":"NCT07075016 - EVOLVE 1","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-07-20"},{"id":"b75ecd93-1120-4cfc-9f9a-b68e1481f48d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588141","created_at":"2022-10-20T14:11:44.038Z","updated_at":"2025-02-25T12:29:09.098Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations","source_id_and_acronym":"NCT05588141","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zotiraciclib (TG02)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/02/2029","study_completion_date":" 08/02/2029","last_update_posted":"2025-02-24"},{"id":"1e4b972b-a78c-437b-a2e3-d4f2e74d347d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03952598","created_at":"2021-01-18T19:27:16.826Z","updated_at":"2025-02-25T13:39:51.583Z","phase":"Phase 2","brief_title":"Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy","source_id_and_acronym":"NCT03952598","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/16/2019","start_date":" 10/16/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"42d928bf-01a8-4f38-bc3e-dbcbf7fa205e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161974","created_at":"2023-12-08T22:16:35.701Z","updated_at":"2025-02-25T13:41:56.353Z","phase":"Phase 2","brief_title":"Study of Olutasidenib and Temozolomide in HGG","source_id_and_acronym":"NCT06161974","lead_sponsor":"Rigel Pharmaceuticals","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Rezlidhia (olutasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2035","study_completion_date":" 06/01/2035","last_update_posted":"2025-02-21"},{"id":"7f66ca0f-1441-4209-9937-3fd50a8da5b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04242849","created_at":"2021-01-18T20:37:36.734Z","updated_at":"2025-02-25T13:40:03.346Z","phase":"","brief_title":"IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up","source_id_and_acronym":"NCT04242849","lead_sponsor":"Josep Carreras Leukaemia Research Institute","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 354","initiation":"Initiation: 05/23/2016","start_date":" 05/23/2016","primary_txt":" Primary completion: 12/27/2019","primary_completion_date":" 12/27/2019","study_txt":" Completion: 01/16/2020","study_completion_date":" 01/16/2020","last_update_posted":"2025-02-21"},{"id":"2da5468a-79d4-4eeb-942f-5b05fa2fb4d8","acronym":"CERTIS1","url":"https://clinicaltrials.gov/study/NCT05417594","created_at":"2022-06-14T22:56:26.797Z","updated_at":"2025-02-25T14:08:54.388Z","phase":"Phase 1/2","brief_title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","source_id_and_acronym":"NCT05417594 - CERTIS1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan-dlnk) • AZD9574"],"overall_status":"Recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 06/24/2022","start_date":" 06/24/2022","primary_txt":" Primary completion: 08/28/2026","primary_completion_date":" 08/28/2026","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-19"},{"id":"b568f31d-6b2b-46ca-879f-a90916765687","acronym":"","url":"https://clinicaltrials.gov/study/NCT05099003","created_at":"2021-10-29T14:53:11.674Z","updated_at":"2025-02-25T14:08:27.717Z","phase":"Phase 1/2","brief_title":"A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)","source_id_and_acronym":"NCT05099003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • IDH1 mutation","tags":["BRAF • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Suspended","enrollment":" Enrollment 210","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-18"},{"id":"22e86fd8-4f8f-4456-992c-88f257edf9a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05345002","created_at":"2022-04-25T21:58:14.873Z","updated_at":"2025-02-25T14:41:19.773Z","phase":"Phase 2","brief_title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","source_id_and_acronym":"NCT05345002","lead_sponsor":"Stephen Bagley, MD, MSCE","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-14"},{"id":"1ed1c0e3-9fae-4441-b5f9-6a5bb4623646","acronym":"","url":"https://clinicaltrials.gov/study/NCT04968366","created_at":"2021-07-20T14:52:28.893Z","updated_at":"2025-02-25T15:44:32.669Z","phase":"Phase 1","brief_title":"Safety \u0026 Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery","source_id_and_acronym":"NCT04968366","lead_sponsor":"Beijing Tiantan Hospital","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/30/2021","start_date":" 07/30/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-11"},{"id":"b172bb8d-07dd-4d40-b459-cb7946457b73","acronym":"NRG-BN007","url":"https://clinicaltrials.gov/study/NCT04396860","created_at":"2021-01-18T21:13:04.295Z","updated_at":"2025-02-25T15:34:40.901Z","phase":"Phase 2/3","brief_title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","source_id_and_acronym":"NCT04396860 - NRG-BN007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • IDH1 • MGMT","pipe":" | ","alterations":" PD-L1 expression • MGMT promoter methylation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MGMT promoter methylation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 04/13/2023","primary_completion_date":" 04/13/2023","study_txt":" Completion: 03/11/2025","study_completion_date":" 03/11/2025","last_update_posted":"2025-02-10"},{"id":"fc5b6895-f7f7-4459-b71c-62a35c47f883","acronym":"ProvIDHe","url":"https://clinicaltrials.gov/study/NCT05876754","created_at":"2023-05-25T15:05:46.429Z","updated_at":"2025-02-25T15:20:32.101Z","phase":"Phase 3","brief_title":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT05876754 - ProvIDHe","lead_sponsor":"Servier Affaires Médicales","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-10"},{"id":"5f8b072a-82e7-4058-ac66-89f1f2f42c46","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576117","created_at":"2021-01-18T21:50:45.604Z","updated_at":"2025-02-25T16:32:16.258Z","phase":"Phase 3","brief_title":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","source_id_and_acronym":"NCT04576117","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1 • NF1","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E","tags":["BRAF • IDH1 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • vinblastine"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 02/16/2021","start_date":" 02/16/2021","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-07"},{"id":"51b4bfec-34ee-4216-99bf-f5a89c3e2090","acronym":"","url":"https://clinicaltrials.gov/study/NCT04056910","created_at":"2021-01-18T19:53:13.460Z","updated_at":"2025-02-25T14:28:34.351Z","phase":"Phase 2","brief_title":"Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors","source_id_and_acronym":"NCT04056910","lead_sponsor":"Jason J. Luke, MD","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tibsovo (ivosidenib)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 11/13/2023","primary_completion_date":" 11/13/2023","study_txt":" Completion: 11/13/2023","study_completion_date":" 11/13/2023","last_update_posted":"2025-02-06"},{"id":"c5be4f65-abfd-49b2-9e6b-92e20f00da7f","acronym":"STING","url":"https://clinicaltrials.gov/study/NCT03048084","created_at":"2021-01-18T15:00:39.333Z","updated_at":"2025-02-25T16:51:48.926Z","phase":"Phase 4","brief_title":"Seizure Treatment in Glioma","source_id_and_acronym":"NCT03048084 - STING","lead_sponsor":"Leiden University Medical Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH wild-type","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-04"},{"id":"0761f5fc-4fb6-468e-bb3d-390adb9bdabf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06113705","created_at":"2023-11-02T15:12:45.694Z","updated_at":"2025-02-25T17:26:31.436Z","phase":"","brief_title":"Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study.","source_id_and_acronym":"NCT06113705","lead_sponsor":"Istituto Clinico Humanitas","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-31"},{"id":"4d0aa8dd-1906-440f-bdc4-7b7bd07db44b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05076513","created_at":"2021-10-13T16:58:18.037Z","updated_at":"2025-02-25T13:12:47.827Z","phase":"Phase 1","brief_title":"Trial of Niraparib in Participants with Newly-diagnosed Glioblastoma and Recurrent Glioma","source_id_and_acronym":"NCT05076513","lead_sponsor":"Nader Sanai","biomarkers":" IDH1 • IDH2 • ATRX","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 03/19/2024","primary_completion_date":" 03/19/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-23"},{"id":"254804cf-c50f-409d-b809-0f0a4043dc18","acronym":"CL1-95032-005","url":"https://clinicaltrials.gov/study/NCT05484622","created_at":"2022-08-02T12:55:57.680Z","updated_at":"2025-02-25T16:18:00.683Z","phase":"Phase 1","brief_title":"Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma","source_id_and_acronym":"NCT05484622 - CL1-95032-005","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Voranigo (vorasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 01/20/2023","start_date":" 01/20/2023","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 08/30/2027","study_completion_date":" 08/30/2027","last_update_posted":"2025-01-14"},{"id":"e68b085a-cda1-45b1-b91f-76f776e1e1a1","acronym":"REGOMA-2","url":"https://clinicaltrials.gov/study/NCT06095375","created_at":"2023-10-23T18:13:31.588Z","updated_at":"2025-02-25T17:26:30.027Z","phase":"Phase 1","brief_title":"Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients","source_id_and_acronym":"NCT06095375 - REGOMA-2","lead_sponsor":"Istituto Oncologico Veneto IRCCS","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Stivarga (regorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 10/09/2024","primary_completion_date":" 10/09/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-24"},{"id":"066ab336-a212-45de-9f07-3f558dc780e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02746081","created_at":"2021-01-18T13:27:15.549Z","updated_at":"2025-02-25T17:08:45.816Z","phase":"Phase 1","brief_title":"Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors","source_id_and_acronym":"NCT02746081","lead_sponsor":"Bayer","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAY1436032"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 05/26/2016","start_date":" 05/26/2016","primary_txt":" Primary completion: 11/08/2018","primary_completion_date":" 11/08/2018","study_txt":" Completion: 12/03/2024","study_completion_date":" 12/03/2024","last_update_posted":"2024-12-18"},{"id":"a154a323-d6ef-4152-926e-c4ab1ae75b5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756777","created_at":"2023-03-06T15:01:58.629Z","updated_at":"2025-02-25T15:36:05.770Z","phase":"Phase 1","brief_title":"A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05756777","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation","tags":["FLT3 • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-11-12"},{"id":"2b8e2f91-c4ad-4a30-bf4b-d41f2c7c9a84","acronym":"INSIGhT","url":"https://clinicaltrials.gov/study/NCT02977780","created_at":"2021-01-18T14:38:25.857Z","updated_at":"2025-02-25T14:36:55.862Z","phase":"Phase 2","brief_title":"INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)","source_id_and_acronym":"NCT02977780 - INSIGhT","lead_sponsor":"Patrick Wen, MD","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Nerlynx (neratinib) • Verzenio (abemaciclib) • CC-115 • QBS72S"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-10-17"}]